[{"orgOrder":0,"company":"SmartCella","sponsor":"Fj\u00e4rde AP-fonden","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"PROC-001","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SmartCella","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SmartCella \/ Fj\u00e4rde AP-fonden","highestDevelopmentStatusID":"14","companyTruncated":"SmartCella \/ Fj\u00e4rde AP-fonden"}]

Find Clinical Drug Pipeline Developments & Deals by SmartCella

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : The financing aims to fund the clinical development of PROC-001, which is being evaluated in the early-stage clinical trial studies for the treatment of cardiovascular diseases such as heart failure.

                          Brand Name : PROC-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 08, 2024

                          Lead Product(s) : PROC-001

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Fjärde AP-fonden

                          Deal Size : $54.1 million

                          Deal Type : Financing

                          blank